MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics

A Shea, V Harish, Z Afzal, J Chijioke, H Kedir… - Cancer …, 2016 - Wiley Online Library
Glioblastoma multiforme (GBM) is the most common and lethal cancer of the adult brain,
remaining incurable with a median survival time of only 15 months. In an effort to identify …

Glioblastoma therapy in the age of molecular medicine

LHM Geraldo, C Garcia, ACC da Fonseca, LGF Dubois… - Trends in cancer, 2019 - cell.com
Glioblastoma (GBM) is the most common and fatal primary malignant brain tumor. Despite
advances in the understanding of the biology of gliomas, little has changed in the treatment …

Brain targeted gold liposomes improve RNAi delivery for glioblastoma

N Grafals-Ruiz, CI Rios-Vicil… - International Journal …, 2020 - Taylor & Francis
Introduction Glioblastoma (GBM) is the most common and lethal of the central nervous
system (CNS) malignancies. The initiation, progression, and infiltration ability of GBMs are …

miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer

Q Lou, R Liu, X Yang, W Li, L Huang, L Wei… - … for immunotherapy of …, 2019 - Springer
Abstract Background Indoleamine 2, 3-dioxygenase 1 (IDO1) is a critical regulator of T cell
function, contributing to immune tolerance. Upregulation of IDO1 has been found in many …

MicroRNAs as biomarkers for human glioblastoma: progress and potential

S Huang, N Ali, L Zhong, J Shi - Acta Pharmacologica Sinica, 2018 - nature.com
Glioblastoma multiforme (GBM) is the most common malignant glioma. Despite innovative
research efforts in tumor therapy, the outcome for most diagnosed patients remains poor; …

Glioblastoma–Astrocyte Connexin 43 Gap Junctions Promote Tumor Invasion

S McCutcheon, DC Spray - Molecular Cancer Research, 2022 - AACR
Glioblastoma multiforme (GBM), classified as World Health Organization grade IV
astrocytoma, is the deadliest adult cancer of the central nervous system. An important …

RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials

EL Lozada-Delgado, N Grafals-Ruiz, PE Vivas-Mejía - Life sciences, 2017 - Elsevier
Glioblastoma multiforme (GBM) is the most common and deadliest type of primary brain
tumor with a prognosis of 14 months after diagnosis. Current treatment for GBM patients …

Deep learning/artificial intelligence and blood-based DNA epigenomic prediction of cerebral palsy

RO Bahado-Singh, S Vishweswaraiah, B Aydas… - International journal of …, 2019 - mdpi.com
The etiology of cerebral palsy (CP) is complex and remains inadequately understood. Early
detection of CP is an important clinical objective as this improves long term outcomes. We …

MicroRNA as potential biomarkers in Glioblastoma

Z Areeb, SS Stylli, R Koldej, DS Ritchie, T Siegal… - Journal of neuro …, 2015 - Springer
Glioblastoma is the most aggressive and lethal tumour of the central nervous system and as
such the identification of reliable prognostic and predictive biomarkers for patient survival …

Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma

D Valle-Garcia, V Pérez de la Cruz, I Flores… - International Journal of …, 2024 - mdpi.com
Glioblastoma (GB) is the most aggressive and common type of cancer within the central
nervous system (CNS). Despite the vast knowledge of its physiopathology and histology, its …